Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quellhorst, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quellhorst, E.
J Am Soc Nephrol 13:S92-S96, 2002
© 2002 American Society of Nephrology

Peritoneal Dialysis

Insulin Therapy during Peritoneal Dialysis: Pros and Cons of Various Forms of Administration

Eduard Quellhorst

Lower Saxony Center of Nephrology, Hann. Muenden, Germany.

Correspondence to Dr. Eduard Quellhorst, Professor of Internal Medicine, Lower Saxony Center of Nephrology, Schützenstr. 102, 34346 Münden, Germany. Phone: +49-5541-33129; Fax: +49-5541-33109; E-mail: equellhorst{at}t-online.de

Abstract

ABSTRACT. Major fluctuations of blood glucose, hyperinsulinemia, and the formation of insulin antibodies can be prevented by intraperitoneal insulin administration during peritoneal dialysis in patients with diabetic nephropathy. The reduction in insulin requirement is most pronounced compared with subcutaneous administration when insulin is instilled into the empty abdominal cavity. If insulin is instilled into the abdominal cavity along with the dialysis fluid, there are losses of activity due to delayed absorption consequential to dilution by the fluid and adsorption to the plastic surface of the dialysis solution delivery systems. These may be so pronounced as to make intraperitoneal administration uneconomical. The effectiveness of peritoneal dialysis is not affected by intraperitoneal insulin administration. The frequency of peritonitis during intraperitoneal insulin administration increases slightly only in continuous ambulatory peritoneal dialysis, but not in intermittent peritoneal dialysis.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
C.-C. Szeto, K.-M. Chow, C.-B. Leung, B. C.-H. Kwan, K.-Y. Chung, M.-C. Law, and P. K.-T. Li
Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1697 - 1702.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
The European Association for the Study of Diabetes
Diabetes Care, May 1, 2005; 28(5): 1250 - 1257.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Preissner, W. M. Reilly, R. C. Cyr, D. J. O'Kane, R. J. Singh, and S. K.G. Grebe
Plastic versus Glass Tubes: Effects on Analytical Performance of Selected Serum and Plasma Hormone Assays
Clin. Chem., July 1, 2004; 50(7): 1245 - 1247.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673